宫颈筛查与腺鳞癌及罕见组织学类型浸润性宫颈癌风险:一项基于人群的巢式病例对照研究
该研究基于瑞典全国登记数据,纳入2002-11年4254例浸润性宫颈癌确诊病例,其中338例非鳞癌非腺癌(164例腺鳞癌、174例罕见类型)。分析显示,与未筛查女性相比,既往两个推荐筛查间隔内接受两次筛查的女性腺鳞癌风险降低(IRR 0.22,95%CI 0.14-0.34),罕见类型风险亦降低(IRR 0.34,95%CI 0.21-0.55)。肿瘤组织中人乳头瘤病毒检测显示148/211(70%)为高危型阳性。
要点
- 宫颈筛查与腺鳞癌及罕见组织学类型浸润性宫颈癌风险降低相关。
- 腺鳞癌IRR 0.22(95%CI 0.14-0.34),罕见类型IRR 0.34(95%CI 0.21-0.55)。
- 多数腺鳞癌和罕见类型宫颈癌高危型HPV阳性(148/211,70%)。
核心结论
- 宫颈筛查与腺鳞癌及罕见组织学类型浸润性宫颈癌风险降低相关,且多数此类肿瘤高危型HPV阳性。
研究设计与样本
- 瑞典全国性基于人群的巢式病例对照研究,纳入2002-11年4254例经临床和组织病理复核确诊的浸润性宫颈癌病例。
主要发现
- 338例非鳞癌非腺癌病例中包括164例腺鳞癌和174例罕见类型(玻璃细胞癌、透明细胞癌、小细胞癌、神经内分泌细胞癌、大细胞癌和未分化癌)。
- 与未接受任何筛查的女性相比,既往两个推荐筛查间隔内接受两次筛查者腺鳞癌风险降低(IRR 0.22,95%CI 0.14-0.34)。
- 相同筛查暴露下罕见类型浸润性宫颈癌风险亦降低(IRR 0.34,95%CI 0.21-0.55)。
- 肿瘤组织HPV检测有效结果211例中148例(70%)检出高危型HPV。
- 高危型HPV阳性肿瘤者(IRR 0.28,95%CI 0.18-0.46)与阴性肿瘤者(IRR 0.27,95%CI 0.13-0.59)筛查相关风险降低程度相似。
关键数值与推荐
- 筛查暴露定义为既往两个推荐筛查间隔内接受两次筛查测试,对照为未接受任何测试。
- 采用条件logistic回归计算比值比并解释为发病率比,按教育程度调整。
临床怎么用
- 结果支持宫颈筛查对腺鳞癌及罕见组织学类型浸润性宫颈癌同样具有保护作用,可作为评估未来筛查策略的基准。
局限性
- 肿瘤HPV检测仅基于部分存档组织,非全部病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the association of cervical cytology screening with the risk of adenosquamous cell carcinoma (ASC) and rare histological types of invasive cervical carcinoma (RICC), using comprehensive registry data, and to assess tumour human papillomavirus status of ASC and RICC. DESIGN: Nationwide, population based, nested case-control study. SETTING: Sweden. PARTICIPANTS: All cases of invasive cervical carcinoma in Sweden during 2002-11 (4254 confirmed cases after clinical and histopathological review). 338 cases were neither squamous cell carcinoma nor adenocarcinoma, including 164 cases of ASC and 174 cases of RICC (glassy cell carcinoma, clear cell carcinoma, small cell carcinoma, neuroendocrine cell carcinoma, large cell carcinoma, and undifferentiated carcinoma). 30 birth year matched controls from the general Swedish population were matched to each case by applying incidence density sampling. MAIN OUTCOME MEASURES: Conditional logistic regression was used to calculate odds ratios, interpreted as incidence rate ratios, for risk of ASC and RICC in relation to screening status and screening history, adjusted for education. Human papillomavirus distribution of ASC and RICC was based on available archival tumour tissues from most Swedish pathology biobanks. RESULTS: Women with two screening tests in the previous two recommended screening intervals had a lower risk of ASC (incidence rate ratio 0.22, 95% confidence interval 0.14 to 0.34) and RICC (0.34, 0.21 to 0.55), compared with women without any test. High risk human papillomavirus was detected in 148/211 (70%) cases with valid human papillomavirus results from tumour tissues. The risk reduction among women with tumours that were positive (incidence rate ratio 0.28, 0.18 to 0.46) and negative (0.27, 0.13 to 0.59) for high risk human papillomavirus was similar, compared with women who did not attend any test. CONCLUSIONS: Cervical screening is associated with reduced risk of ASC and RICC, and most ASC and RICC are positive for high risk human papillomavirus. This evidence provides a benchmark for evaluating future cervical screening strategies.
引用
- Lei J, Andrae B, Ploner A, et al. Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. BMJ. 2019. PMID: 30944091. doi:10.1136/bmj.l1207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。